Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (Minibody) is designed to be expressed as the anti-CD89 scFv fused to N-terminus of Knob-CH3 domain and the anti-EGFR scFv to the Hole-CH3 domain, or vice versa. The CH3 domains are further stabilized by C-terminal disulfide bonds. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY